ClinicalTrials.gg
CompletedNCT03915691Updated Oct 19, 2026

The RIPPLE AT-PLUS Study

An interventional study of Catheter ablation of atrial tachycardia: Ripple Mapping guided. and Catheter ablation of atrial tachycardia: Conventional mapping guided. in Atrial Tachycardia, sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 307 studies in Atrial Fibrillation with a site in United Kingdom — 42 open to participants now, 71 under way, 5 of them phase 3. Atrial Fibrillation · United Kingdom.

Enrollment
86th of 207
201 · median 152
Started
2022
with 21 others
No phase
125 of 307
19 open now
Registered
182nd of 307
by date
Lead sponsor
9 of 307
Liverpool Heart and Chest Hospital NHS Foundation Trust

Among the 307 studies in Atrial Fibrillation with a site in United Kingdom, this one is the 86th largest by enrollment of the 207 interventional ones that give a count, is one of 22 that started in 2022, is one of 125 with no phase, and was the 182nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

42 of the 307 studies in Atrial Fibrillation with a site in United Kingdom are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 307 studies in Atrial Fibrillation with a site in United Kingdom, or all of them as a file.
02

Study summary

Atrial tachycardia is a symptomatic arrhythmia, for which an effective treatment is a catheter ablation procedure. The goal of the Ripple AT-Plus study is to evaluate two methods of performing catheter ablation for atrial tachycardia. The main outcome assessed during the study is long-term recurrence of atrial tachycardia following the catheter ablation procedure.

Read the detailed description

Catheter based mapping of the electrical signals in the heart during atrial tachycardia can identify areas that require ablation in order to treat the arrhythmia. There are numerous methods by which to map atrial tachycardia. Isthmus guided ablation using Ripple Mapping is one such method, and has recently been demonstrated to improve diagnostic accuracy of mapping and therefore improve acute procedural outcomes (termination of the tachycardia).

However, it is not known if improved acute procedural outcomes translate into long-term benefits for patients. At present, the recurrence rate following atrial tachycardia ablation is near 30%. We hypothesise that isthmus guided ablation using Ripple Mapping can reduce long-term recurrence following ablation as improved diagnostic accuracy of mapping can lead to more targeted, less extensive, ablation.

Patients referred for catheter ablation of atrial tachycardia will be randomised to undergo the procedure by isthmus targeted approach using Ripple Mapping or conventional approach using local activation time. Otherwise, the catheters used to perform the mapping and ablation will be the same in both groups. After the procedure, follow up will occur at 1 year with a further Holter Montior. Any arrhythmia recurrence will be documented and the two arms will be compared for acute success, 12 month success, ablation required and procedure time.

03

Conditions studied

  • Atrial Tachycardia

Browse trials for

Keywords

  • Atrial Tachycardia
  • Atrial Fibrillation
  • Mapping
  • Ablation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Referred for catheter ablation of AT by the direct care team, based on clinical indication.
  2. Male or female, aged >18 years old.
  3. Able to consent for recruitment to the trial and the catheter ablation procedure.

Exclusion criteria

Exclusion Criteria:

  1. to catheter ablation as deemed by the clinical team.
  2. Typical atrial flutter or AF on .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Active comparator
    Isthmus targeted approach using Ripple Mapping

    Intervention: Isthmus targeted approach using Ripple Mapping catheter ablation of atrial tachycardia.

    Procedure: Catheter ablation of atrial tachycardia: Ripple Mapping guided.

  • Active comparator
    Conventional Mapping

    Intervention: conventional catheter ablation of atrial tachycardia.

    Procedure: Catheter ablation of atrial tachycardia: Conventional mapping guided.

Interventions

  • ProcedureCatheter ablation of atrial tachycardia: Ripple Mapping guided.

    Ripple Mapping is used to map the atrial tachycardia mechanism. Using the scar thresholding technique the Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.

  • ProcedureCatheter ablation of atrial tachycardia: Conventional mapping guided.

    Conventional activation mapping is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.

06

What researchers measure

Primary outcomes

  1. Atrial arrhythmia recurrence

    Any confirmed episode of atrial arrhythmia (\>30 seconds on Holter or 12 lead ECG) occurring in the 12 months after catheter ablation.

    Time frame: 12 months

Secondary outcomes

  1. Acute success during the catheter ablation procedure by the first ablation set.

    Atrial tachycardia termination (acute success) during ablation delivered to only target the diagnosed AT mechanism by the mapping approach used (first ablation set).

    Time frame: Procedure.

  2. Acute success during the catheter ablation procedure without the need of entrainment.

    Entrainment not required to confirm or exclude the diagnosis made by 3D electroanatomic mapping methods.

    Time frame: Procedure.

  3. Procedure failure.

    Inability to terminate atrial tachycardia during the catheter ablation procedure, requiring external electrical cardioversion to achieve sinus rhythm.

    Time frame: Procedure.

  4. Total procedure time.

    Procedure time measured from initiation of intracardiac mapping to catheter removal from the body.

    Time frame: Procedure.

  5. Ablation required

    Ablation required, measured using pre-defined ablation index or ablation line length.

    Time frame: Procedure.

07

Study locations

3 sites
  • Liverpool Heart & Chest Hospital
    London, L14 3PE, United Kingdom
  • Imperial College Healthcare NHS Trust
    London, W12 0HS, United Kingdom
  • Freeman Hospital, The Newcastle Upon Tyne NHS Foundation Trust
    Newcastle, NE7 7DN, United Kingdom
08

References and documents

Publications

  • Kailey B, Kemp I, Taylor M, Crooks J, Katritsis G, Koa-Wing M, Jamil-Copley S, Linton N, Kanagaratnam P, Gupta D, Luther V. Ripple AT Plus - isthmus-guided vs conventional ablation in the treatment of scar-related atrial tachycardia: study protocol for a randomised controlled trial. J Interv Card Electrophysiol. 2023 Oct;66(7):1533-1539. doi: 10.1007/s10840-023-01607-8. Epub 2023 Aug 18. PubMed 37594646 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jun 2025, 33 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 33 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Apr 2026 → Jun 2025 and completion Apr 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
Apr 16, 2019
StartActual
Aug 16, 2022
Primary completionActual
Jun 3, 2025was Apr 2026
CompletionActual
Jun 3, 2026was Apr 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 19, 2026
Primary completion
Apr 2026→Jun 3, 2025 (actual)
Oct 19, 2026
Study completion
Apr 2026→Jun 3, 2026 (actual)
Oct 19, 2026
Sponsor
Collaborators added: Norfolk and Norwich University Hospitals NHS Foundation Trust·Blackpool Teaching Hospitals NHS Foundation Trust·Cardiff and Vale University Health Board; collaborators removed: Norfolk & Norwich University Hospital Trust·Blackpool Teaching Hospitals NHS Trust·Cardiff & Vale UHB
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Completed
    Primary completion Apr 2026→Jun 3, 2025 (now actual)
    Study completion Apr 2026→Jun 3, 2026 (now actual)
    Sponsor Collaborators added: Norfolk and Norwich University Hospitals NHS Foundation Trust·Blackpool Teaching Hospitals NHS Foundation Trust·Cardiff and Vale University Health Board; collaborators removed: Norfolk & Norwich University Hospital Trust·Blackpool Teaching Hospitals NHS Trust·Cardiff & Vale UHB
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03915691
Lead sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Collaborators
Imperial College Healthcare NHS Trust, Norfolk and Norwich University Hospitals NHS Foundation Trust, Nottingham University Hospitals NHS Trust, University Hospital Plymouth NHS Trust, Blackpool Teaching Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, University Hospitals Sussex NHS Foundation Trust
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Aug 16, 2022
Primary completion
Jun 3, 2025
Completion
Jun 3, 2026
Last update
Oct 19, 2026

Study contacts

Vishal Luther, MBBS
principal investigator · Liverpool Heart & Chest Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion